XML 30 R17.htm IDEA: XBRL DOCUMENT
v3.26.1

Stockholders' Equity | 3 Months Ended
--- | ---
Apr. 30, 2026
Share-Based Payment Arrangement [Abstract] |
Stockholders' Equity | Stockholders’ Equity Common Stock As of April 30, 2026, we had 162,942,747 shares of common stock outstanding. Stock Option Activity A summary of stock option activity for the three months ended April 30, 2026 is as follows:
| Number of shares |  | Weighted average exercise price |  | Weighted average remaining contractual term (in years) |  | Aggregate intrinsic value (in millions)
Options outstanding at January 31, 2026 | 15,134,876 |  |  | $ | 181.99 |  |  | 6.3 |  | $ | 523 |
Options granted | 97,300 |  |  | $ | 175.42 |  |  |  |  |
Options exercised | (19,448) |  |  | $ | 151.04 |  |  |  |  |
Options forfeited/cancelled | (91,993) |  |  | $ | 216.62 |  |  |  |  |
Options outstanding at April 30, 2026 | 15,120,735 |  |  | $ | 181.78 |  |  | 6.0 |  | $ | 291 |
Options vested and exercisable at April 30, 2026 | 9,444,451 |  |  | $ | 159.56 |  |  | 4.8 |  | $ | 291 |
Options vested and exercisable at April 30, 2026 and expected to vest thereafter | 15,120,735 |  |  | $ | 181.78 |  |  | 6.0 |  | $ | 291 |
As of April 30, 2026, there was $365 million in unrecognized compensation cost related to unvested stock options granted under the 2013 Equity Incentive Plan. This cost is expected to be recognized over a weighted average period of 2.2 years. The grant-date fair value of options vested was $253 million and $128 million for the three months ended April 30, 2026 and 2025, respectively. The weighted average grant-date fair value of options granted was $79.15 and $96.83 per option for the three months ended April 30, 2026 and 2025, respectively. The total intrinsic value of options exercised was approximately $1 million and $16 million for the three months ended April 30, 2026 and 2025, respectively. Stock Option Valuation Assumptions The following table presents the weighted-average assumptions used to estimate the grant date fair value of options granted during the periods presented:
|  |  |  | Three months ended April 30,
|  |  |  |  |  | 2026 |  | 2025 |  |
Volatility |  |  |  |  |  |  |  |  |  | 39% | - | 40% |  | 39% | - | 40% |  |  |  |
Expected term (in years) |  |  |  |  |  |  |  | 6.3 |  | 6.3 | - | 7.0 |  |  |  |
Risk-free interest rate |  |  |  |  |  |  |  |  |  | 3.7% | - | 4.0% |  | 3.8% | - | 4.4% |  |  |  |
Dividend yield |  |  |  |  |  | —% |  | —% |  |
Restricted Stock Units (“RSUs”) A summary of RSU activity for the three months ended April 30, 2026 is as follows:
| Unreleased restricted stock units |  | Weighted average grant date fair value
Balance at January 31, 2026 | 890,056 |  |  | $ | 211.42 |
RSUs granted | 3,867,310 |  |  | $ | 173.52 |
RSUs vested | (648,811) |  |  | $ | 211.79 |
RSUs forfeited/cancelled | (19,053) |  |  | $ | 184.31 |
Balance at April 30, 2026 | 4,089,502 |  |  | $ | 175.65 |
As of April 30, 2026, there was a total of $667 million in unrecognized compensation cost related to unvested RSUs. This cost is expected to be recognized over a weighted-average period of approximately 2.8 years. The total fair value of RSUs vested was $112 million and $54 million for the three months ended April 30, 2026 and 2025, respectively. The RSUs granted during the three months ended April 30, 2026 primarily consisted of awards made in connection with our annual compensation review cycle that vest over one year or at the completion of four years. The weighted average grant-date fair value of RSUs granted was $173.52 and $214.17 per award for the three months ended April 30, 2026 and 2025, respectively. In April 2026, we transitioned our long-term equity incentive for employees (excluding our CEO) from annual stock option grants to RSUs that generally cliff-vest after four years of continuous service (each a "Long-Term Grant"). Long-Term Grants are generally not expected to be annually recurring, and eligible employees are generally expected to be limited to a single Long-Term Grant at any point in time. Share Repurchase Program In January 2026, our board of directors authorized a share repurchase program of up to $2 billion of our outstanding shares of common stock. Under the program, we may repurchase shares of common stock from time to time through open market purchases, in privately negotiated transactions, or by other means, including through the use of trading plans intended to qualify under Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), in accordance with applicable securities laws and other restrictions, including Rule 10b-18 under the Exchange Act. The timing and total amount of any share repurchases depend upon business, economic and market conditions, corporate and regulatory requirements, prevailing stock prices, and other considerations. The share repurchase program has a term of two years, may be suspended or discontinued at any time, and does not obligate us to acquire any amount of common stock. Any repurchased shares of common stock are retired. The table below sets forth information regarding repurchase of shares under our share repurchase program (in thousands, except number of shares and per share data):
|  |  | Three months ended April 30,
|  |  |  |  | 2026 |  |  |  |
Total number of shares repurchased |  |  |  |  | 1,255,029 |  |  |  |  |
Average price paid per share (1) |  |  |  |  | $ | 176.17 |  |  |  |  |
Amount repurchased (1) |  |  |  |  | $ | 221,100 |  |  |  |  |
(1) Amounts exclude commissions and excise taxes.
All repurchases were made in open market transactions. As of April 30, 2026, $1.6 billion remained available for future repurchase.

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP). + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContent Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/505/tableOfContent + Details
Name: | us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration